Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention
Year: 2020
Type: review
Abstract: Development of improved approaches for HIV-1 prevention will likely be required for a durable end to the global AIDS pandemic. Recent advances in preclinical studies and early phase clinical trials offer renewed promise for immunologic strategies for blocking acquisition of HIV-1 infection. Clinical trials are currently underway to evaluate the efficacy of two vaccine candidates and a broadly neutralizing antibody (bNAb) to prevent HIV-1 infection in humans. However, the vast diversity of HIV-1 is a major challenge for both active and passive immunization. Here we review current immunologic strategies for HIV-1 prevention, with a focus on current and next-generation vaccines and bNAbs.
Source: Annual Review of Immunology
Language: English
Topic: HIV Research and Treatment
Subfield: Virology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: green
Awards: Optimization of Broadly Neutralizing Antibodies for HIV Eradication, Consortia for Innovative AIDS Research in Nonhuman Primates, Impact of the Intestinal Microbiome on HIV/SIV Vaccines, Combined Immunologic Approaches to Cure HIV-1, Diversity of Immune Responses Elicited by HIV Vaccines, Development of Ad26/Env Vaccines for HIV, SHIV Env-antibody coevolution as a molecular guide to HIV-1 V3 glycan targeted vaccine design, Optimizing glycan shield coverage, germline B cell receptor binding and epitope diversity of V2-apex targeted HIV-1 Env immunogens
OpenAlex ID: W3020606853